Gregory M. Glenn - Sep 30, 2021 Form 4 Insider Report for NOVAVAX INC (NVAX)

Signature
/s/ John A. Herrmann III, Attorney-in-Fact
Stock symbol
NVAX
Transactions as of
Sep 30, 2021
Transactions value $
-$143,622
Form type
4
Date filed
10/1/2021, 05:58 PM
Previous filing
Sep 29, 2021
Next filing
Oct 7, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Sale -$10.3K -51 -1.07% $202.84 4.7K Sep 30, 2021 Direct F1, F2
transaction NVAX Common Stock Sale -$11.2K -55 -1.17% $203.94 4.65K Sep 30, 2021 Direct F1, F3
transaction NVAX Common Stock Sale -$3.28K -16 -0.34% $205.01 4.63K Sep 30, 2021 Direct F1
transaction NVAX Common Stock Sale -$58K -280 -6.04% $207.01 4.35K Sep 30, 2021 Direct F1, F4
transaction NVAX Common Stock Sale -$24.3K -117 -2.69% $207.99 4.24K Sep 30, 2021 Direct F1, F5
transaction NVAX Common Stock Sale -$24.7K -118 -2.79% $209.27 4.12K Sep 30, 2021 Direct F1, F6
transaction NVAX Common Stock Sale -$8.41K -40 -0.97% $210.16 4.08K Sep 30, 2021 Direct F1, F7
transaction NVAX Common Stock Sale -$3.38K -16 -0.39% $211.39 4.06K Sep 30, 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.49 to $203.31, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F3 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.67 to $204.31, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F4 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $206.58 to $207.50, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F5 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $207.75 to $208.38, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F6 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $208.76 to $209.74, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F7 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.08 to $210.35, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.